The Challenges of Iran's Type 2 Diabetes Prevention and Control Program.
Diabetes mellitus
health plan implementation
prevention and control
type 2
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
09
2017
accepted:
13
11
2017
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
Incidence and prevalence of type 2 diabetes are one of the major challenges of Iran health system. Despite policies on diabetes prevention and control, Iran is faced with many problems in prevention and control of this disease at the executive level. This study seeks to identify the problems of Type 2 diabetes prevention and control program in Iran. In this qualitative study, 17 participants were interviewed purposefully. The semi-structured interview guide was designed based on literature review and four initial in-depth interviews. Framework analysis method was used for the analysis of qualitative data. Six themes and 29 subthemes explaining the problems of type 2 diabetes prevention and control program were identified: Referral system, human resources, infrastructure, cultural problems, access, and intersectoral coordination issues. Despite the well-developed policy of type 2 diabetes prevention and control, the implementation is faced with some problems which endangers the effectiveness of the plan. Any attempt to improve the successful implementation of the type 2 diabetes prevention and control program requires effective measures, deep understanding of the problems and solving them.
Sections du résumé
BACKGROUND
BACKGROUND
Incidence and prevalence of type 2 diabetes are one of the major challenges of Iran health system. Despite policies on diabetes prevention and control, Iran is faced with many problems in prevention and control of this disease at the executive level. This study seeks to identify the problems of Type 2 diabetes prevention and control program in Iran.
METHODS
METHODS
In this qualitative study, 17 participants were interviewed purposefully. The semi-structured interview guide was designed based on literature review and four initial in-depth interviews. Framework analysis method was used for the analysis of qualitative data.
RESULTS
RESULTS
Six themes and 29 subthemes explaining the problems of type 2 diabetes prevention and control program were identified: Referral system, human resources, infrastructure, cultural problems, access, and intersectoral coordination issues.
CONCLUSIONS
CONCLUSIONS
Despite the well-developed policy of type 2 diabetes prevention and control, the implementation is faced with some problems which endangers the effectiveness of the plan. Any attempt to improve the successful implementation of the type 2 diabetes prevention and control program requires effective measures, deep understanding of the problems and solving them.
Identifiants
pubmed: 32133093
doi: 10.4103/ijpvm.IJPVM_371_17
pii: IJPVM-10-175
pmc: PMC6826765
doi:
Types de publication
Journal Article
Langues
eng
Pagination
175Informations de copyright
Copyright: © 2019 International Journal of Preventive Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Diabetes Metab Res Rev. 2000 Sep-Oct;16 Suppl 1:S84-92
pubmed: 11054895
Iran Red Crescent Med J. 2012 Dec;14(12):758-63
pubmed: 23482866
J Am Podiatr Med Assoc. 1996 Sep;86(9):421-6
pubmed: 8885604
BMC Med Educ. 2008 Apr 17;8:22
pubmed: 18419804
Am J Manag Care. 2007 Dec;13(12):670-6
pubmed: 18069910
Am Fam Physician. 2009 Jan 1;79(1):29-36
pubmed: 19145963
Diabetes Care. 2000 Apr;23(4):477-83
pubmed: 10857938
Mater Sociomed. 2016 Jun;28(3):196-200
pubmed: 27482161
Diabetes Care. 2000 Apr;23(4):472-6
pubmed: 10857937
J Foot Ankle Surg. 1999 Jan-Feb;38(1):30-3; discussion 82-3
pubmed: 10028467
Diabetes Educ. 2009 Nov-Dec;35(6):1014-22
pubmed: 19934459
Diabetes Care. 2005 Jan;28 Suppl 1:S37-42
pubmed: 15618111
West J Med. 1997 Sep;167(3):138-44
pubmed: 9308405
West J Med. 2001 Mar;174(3):175-9
pubmed: 11238348
Lancet. 2010 Nov 20;376(9754):1785-97
pubmed: 21074253
East Mediterr Health J. 2003 Sep-Nov;9(5-6):1114-21
pubmed: 16450545
BMC Fam Pract. 2005 May 12;6(1):20
pubmed: 15890071
J Gen Intern Med. 2007 Apr;22(4):464-9
pubmed: 17372794
Diabet Med. 2001 Aug;18(8):671-4
pubmed: 11553207
Lancet. 2007 Apr 14;369(9569):1277-1285
pubmed: 17434403
N Z Med J. 1999 Oct 8;112(1097):383-5
pubmed: 10587070
Am J Med. 2013 Sep;126(9 Suppl 1):S38-48
pubmed: 23953078
Dis Manag. 2006 Aug;9(4):242-56
pubmed: 16893337
Diabetes Educ. 1991 Jan-Feb;17(1):37-41
pubmed: 1986902
Osong Public Health Res Perspect. 2016 Oct;7(5):296-300
pubmed: 27812487
Clin Infect Dis. 2004 Oct 1;39(7):885-910
pubmed: 15472838
S Afr Med J. 2005 Oct;95(10):798-802
pubmed: 16341336
Emerg Med J. 2003 Mar;20(2):184-7
pubmed: 12642541
J Gen Intern Med. 2008 Jul;23(7):937-41
pubmed: 18612720
Prog Lipid Res. 2009 Jan;48(1):44-51
pubmed: 19032965
Bull World Health Organ. 2010 May;88(5):342-9
pubmed: 20461138
JAMA. 2002 Aug 21;288(7):889-93
pubmed: 12186609
Dis Manag. 2006 Jun;9(3):144-56
pubmed: 16764532
Diabetes Care. 2001 Oct;24(10):1821-33
pubmed: 11574449
Diabetes Educ. 2005 Jan-Feb;31(1):75-83
pubmed: 15779248
Diabetes Res Clin Pract. 2010 Mar;87(3):293-301
pubmed: 20171754
World Health Forum. 1991;12(1):38-42
pubmed: 1859596
Diabetes Res Clin Pract. 2011 Dec;94(3):311-21
pubmed: 22079683
Int J Health Policy Manag. 2013 Jul 18;1(2):157-62
pubmed: 24596856
Endocr Pract. 2011 Mar-Apr;17 Suppl 2:1-53
pubmed: 21474420
AIDS. 2003 Jul;17 Suppl 3:S103-8
pubmed: 14565616
Curr Med Res Opin. 2009 Jun;25(6):1413-20
pubmed: 19422281
Clin Cornerstone. 2007;8(2):33-40; discussion 41-3
pubmed: 18357954
Patient Educ Couns. 1995 Sep;26(1-3):57-66
pubmed: 7494756
Fam Pract. 2002 Aug;19(4):344-9
pubmed: 12110552
Diabetes Care. 1998 Sep;21(9):1414-31
pubmed: 9727886
Diabetes Care. 2005 Oct;28(10):2543-5
pubmed: 16186296